TY - CONF T1 - DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation JO - ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY PY - 2020/01/01 AU - Sengupta S AU - Niazi T AU - Williams S AU - Davis ID AU - Stockler M AU - Martin AJ AU - Bracken K AU - Roncolato FT AU - McJannett M AU - Horvath L AU - Hughes S et al ED - VL - 16 SP - 204 EP - 204 Y2 - 2025/03/13 ER -